Salud financiera de hoja de balance de Halozyme Therapeutics
Salud financiera controles de criterios 3/6
Halozyme Therapeutics tiene un patrimonio de accionistas total de $83.8M y una deuda total de $1.5B, lo que sitúa su ratio deuda-patrimonio en 1788.9%. Sus activos y pasivos totales son $1.7B y $1.6B respectivamente. El BAIT de Halozyme Therapeutics es de $340.1M, por lo que su ratio de cobertura de intereses es de 38.8. Tiene efectivo e inversiones a corto plazo que ascienden a $336.0M.
Información clave
844.1%
Ratio deuda-patrimonio
US$1.50b
Deuda
| Ratio de cobertura de intereses | 43.7x |
| Efectivo | US$463.45m |
| Patrimonio | US$177.81m |
| Total pasivo | US$1.66b |
| Activos totales | US$1.84b |
Actualizaciones recientes sobre salud financiera
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Recent updates
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today
Sep 08Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Aug 16Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off
Aug 03Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Jun 10Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($746.4M) de HALO superan a sus pasivos a corto plazo ($112.5M).
Pasivo a largo plazo: Los activos a corto plazo ($746.4M) de HALO no cubren sus pasivos a largo plazo ($1.5B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de HALO (1388%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de HALO ha crecido de 50.8% a 1788.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de HALO está bien cubierta por el flujo de caja operativo (25.9%).
Cobertura de intereses: Los pagos de intereses de la deuda de HALO están bien cubiertos por el BAIT (38.8x cobertura).